Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?

Molecular and Cellular Biochemistry

Volumn 433, Issue 1-2, 2017, Pages 97-102

  Shi, Xingjuan ^a,c,d   Verma, Subodh ^a,b,c   Yun, Junghwa ^a   Brand Arzamendi, Koroboshka ^a,c   Singh, Krishna K ^b,c   Liu, Xiangdong ^d   Garg, Ankit ^b   Quan, Adrian ^b   Wen, Xiao Yan ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SOUTHEAST UNIVERSITY   (China)

Author keywords

Biomarkers; Empagliflozin; Heart failure; Zebrafish

Indexed keywords

ARISTOLOCHIC ACID; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYCLOOXYGENASE 2; EMPAGLIFLOZIN; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; MYOCYTE ENHANCER FACTOR 2; RIBOSOMAL PROTEIN L13A; RIBOSOME PROTEIN; SODIUM GLUCOSE COTRANSPORTER 2; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG; ARISTOLOCHIC ACID C; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; EMBRYO; EMBRYO MORTALITY; EXON; HEART EDEMA; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; LUCIFERASE ASSAY; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC ZEBRAFISH; ANIMAL; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DISEASE MODEL; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; TRANSGENIC ANIMAL; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARISTOLOCHIC ACIDS; BENZHYDRYL COMPOUNDS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSIDES; HEART FAILURE; HUMANS; MALE; ZEBRAFISH;

EID: 85017099681     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-017-3018-9     Document Type: Article

References (8)

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE and Investigators E-RO (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. doi:10.1056/NEJMoa1504720
2. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA (2016) SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care 39:717–725. doi:10.2337/dc16-0041
3. Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care 39:1108–1114. doi:10.2337/dc16-0330
4. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ (2016) SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339. doi:10.1007/s00125-016-3956-x
5. Huang CC, Monte A, Cook JM, Kabir MS, Peterson KP (2013) Zebrafish heart failure models for the evaluation of chemical probes and drugs. Assay Drug Dev Technol 11:561–572. doi:10.1089/adt.2013.548
6. Becker JR, Robinson TY, Sachidanandan C, Kelly AE, Coy S, Peterson RT, MacRae CA (2012) In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signalling. Cardiovasc Res 93:463–470. doi:10.1093/cvr/cvr350
7. Lopaschuk GD, Verma S (2016) Empagliflozin’s fuel hypothesis: not so soon. Cell Metab 24:200–202. doi:10.1016/j.cmet.2016.07.018
8. Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A, Teoh H, Mazer CD, Connelly KA (2016) Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. doi:10.2337/dc16-1312